INTESTINAL Publication-derived

Patient-Derived CRC Organoids Predict Chemotherapy Response

Source Ooft et al. · Princess Máxima Center and Hubrecht Institute, Utrecht, Netherlands

👤 Ooft SN, Weeber F, Dijkstra KK, McLean CM, Lorber S, Maaskant JJ, Huitema S, Templeton A, Clevers H, Voest EE ⏱ 21600 min 🧫 Patient-Derived (CRC Tumor Biopsies, Multi-Center)

Abstract

Demonstrated that patient-derived CRC organoids can predict clinical response to irinotecan-based chemotherapy regimens in metastatic colorectal cancer. Prospective validation showed organoid drug sensitivity testing could be completed within clinical timelines, enabling real-world implementation.

Cell source

Patient-Derived (CRC Tumor Biopsies, Multi-Center)

Application

Chemotherapy Selection

Full SOP

🔬

Create a free account to access this protocol

Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.

Create free account

Already registered? Log in

Attribution

This SOP was authored by Organthis based on the published method in Ooft et al.. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.

This wording is awaiting legal review.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?

Use this protocol in your therapeutic or diagnostic pipeline.

Request Commercial Licence